Dimensional Fund Advisors’s Seres Therapeutics MCRB Stock Holding History

Dimensional Fund Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$228K	Sell	1,774 -25,364	-93%	-$2.6M	﹤0.01%	3215
2022 Q2	$1.86M	Buy	27,138 +3,722	+16%	+$321K	﹤0.01%	2761
2022 Q1	$3.33M	Buy	+23,416	New	+$3.6M	﹤0.01%	2665
2017 Q4	–	Sell	-1,785	Closed	-$573K	–	3332
2017 Q3	$573K	Sell	1,785 -45	-2%	-$12.3K	﹤0.01%	3086
2017 Q2	$414K	Buy	1,830 +574	+46%	+$118K	﹤0.01%	3119
2017 Q1	$283K	Buy	+1,256	New	+$255K	﹤0.01%	3163

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Dimensional Fund Advisors's MCRB Position: Q3 2022 in Review

Dimensional Fund Advisors reduced its Seres Therapeutics (MCRB) stake by 93% in Q3 2022, selling an estimated $2.6M and leaving 1,774 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

Dimensional Fund Advisors first reported a position in MCRB in Q1 2017 and has held it in 6 quarters since. The position peaked at $3.33M in Q1 2022. 119 funds tracked by Wall St. Rank hold MCRB as of Q3 2022.

Dimensional Fund Advisors held 1,774 shares of Seres Therapeutics worth $228K as of Q3 2022.
Dimensional Fund Advisors sold 25,364 Seres Therapeutics shares in Q3 2022, an estimated $2.6M.
Seres Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2022, its #3215 holding.
Dimensional Fund Advisors first reported a position in Seres Therapeutics in Q1 2017 and has held it in 6 quarters since.
Dimensional Fund Advisors's Seres Therapeutics position peaked at $3.33M in Q1 2022.
119 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2022.

Based on Dimensional Fund Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.